Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)

• Status: Not yet recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Objective of this study is to determine the clinical benefits of itopride in improvement of MAFLD

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: October 6 University
• Collaborator: Beni-Suef University
• Treatments: Antihypertensive Agents; Hypolipidemic Agents

Criteria

Inclusion Criteria:

• Patients presented to hepatology clinic . -Patients are diagnosed by ultrasonography and laboratory tests for liver and lipids. - -

• Patients with comorbidites like hypertension,diabetes,dyslipidemia

Exclusion Criteria:

• Exclusion criteria included the presence of liver disease due to any of the following:

viral hepatitis (HBV, HCV)

• acute systemic disease

• cystic fibrosis, coeliac disease

• suspicion of muscular dystrophy, alpha-1-antitrypsin deficiency

• metabolic inherited diseases

• autoimmune hepatitis, drug toxicity and drugs known to induce steatosis (e.g. valproate, amiodarone orprednisone).

• Patients were also excluded if body weight and carbohydrate metabolism were altered by the use of parenteral nutrition

• protein malnutrition

• previous gastrointestinal surgery

• structural abnormalitiesof the gastrointestinal tract or neurological impairment.

• the use of nonsteroidal anti-inflammatory drugs,antibiotics,sglt2,dpp4,statins,glp1

• probiotics or anti-secretory drugs capable of causing achlorhydria within 2 months preceding enrolmentwere also considered exclusion criteria.

• Patient with age below 18 or above 60